Appian and PSI CRO Form Strategic Partnership to Advance AI-driven Clinical Trial Operations

What happened

Appian and PSI CRO launched their first joint AI-powered process orchestration solution, which automates clinical trial site identification and selection across therapeutic areas, indications, and geographies. The live solution is the first step in a shared platform strategy covering the full clinical trial lifecycle.

Confirmed

Global impact / market context

For Appian, the partnership puts its platform into a live clinical trial use case, which could support software revenue and show that automation can replace manual, decentralised steps. For PSI CRO, faster site selection may reduce delays and costs in running studies for sponsors.

Analyst inference

Clinical trial site selection involves many stakeholders, large documentation volumes, and parallel activities across countries. A solution that brings these steps into one digital process could shift spending toward automation platforms, though the article gives no contract value, revenue figures, or adoption numbers.

Analyst inference

What to watch

1. Appian and PSI CRO describe the launch as the first step in a shared vision to connect automation, AI capabilities, and process orchestration across the full clinical trial lifecycle. Confirmed
2. Watch whether the companies extend the platform beyond site selection into later trial stages, since the article says the broader platform strategy is still being built. Proposed
3. Watch for adoption evidence such as sponsors using the live solution, because without disclosed deal value or customer numbers the financial benefit to Appian remains unproven. Analyst inference

Evidence

• Original source link unavailable